haematology general-medicine
VTE-BLEED Score
Estimates major bleeding risk in patients on anticoagulation for VTE to guide duration of treatment.
Score interpretation
Low Bleeding Risk 0–1.9
Low risk of major bleeding on anticoagulation
→ Extended anticoagulation likely safe if VTE recurrence risk is high
High Bleeding Risk 2–10
High risk of major bleeding on anticoagulation
→ Limit anticoagulation to 3–6 months; weigh risks/benefits carefully
Interpretation bands for the VTE-BLEED. Apply clinical judgement and local guidance.
References
- Klok FA et al. Derivation and external validation of a simple risk score to predict VTE-related bleeding in patients treated for acute VTE. Thromb Haemost. 2016;116(6):1065–1071.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Warfarin · Anticoagulant
- Enoxaparin (LMWH) · Anticoagulant
- Bivalirudin (PCI Anticoagulation) · Direct Thrombin Inhibitor / PCI
- Prothrombin Complex Concentrate (PCC) · Coagulation Factor Concentrate — Warfarin Reversal
- Vasopressin / Terlipressin · Vasopressin Analogue — Vasodilatory Shock / Variceal Bleeding
- Bivalirudin · Anticoagulation
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.